Erscheinungsdatum: 06.03.2019, Medium: Buch, Einband: Gebunden, Titel: ABO-incompatible Organ Transplantation, Auflage: 2019, Redaktion: Wang, Yi, Verlag: Springer-Verlag GmbH // Springer Singapore, Sprache: Englisch, Schlagworte: Chirurgie // Plastische Chirurgie // Operation // medizinisch // Transplantation // Medizin // Spezialgebiete // MEDICAL // Surgery // General // Transplantationschirurgie // Klinische und Innere Medizin // Medizinische Spezialgebiete, Rubrik: Medizin // Andere Fachgebiete, Seiten: 274, Abbildungen: 7 schwarz-weiße und 5 farbige Abbildungen, 20 farbige Tabellen, Bibliographie, Informationen: Book, Gewicht: 641 gr, Verkäufer: averdo
This book introduces the clinical application of ABO-incompatible transplantation. In the first part, it starts with the history, blood group antigen, antibody associated with ABO blood type, pathophysiology and pathology and related knowledge. In the second part, it covers clinical experience sharing of ABO-incompatible of heart, liver, lung and kidney transplantation. It provides a systematic methodologies and protocols.
The fourth edition will give a new, complete overview of the therapeutic apheresis (TA) with all semi- and selective methods, which are available. All methods, their functions, indications, clinical results, criticisms, and future aspects are discussed. This edition contains 580 pages including 117 tables, 85 figures, and 3380 references. In 6 chapters historical highlights, methods of unselective, semi-selective and selective separation procedures, complications, side effects of TA, and clinical results of different diseases are mentioned. Possible indications of TA are shown in pediatric diseases. Semi-selective and selective separation methods such as cascade-filtration, cryofiltration, plasmaperfusion, fibrinogen-adsorption, different methods of Immunoadsorption, LDL-apheresis, LDL hemoperfusion, and other methods, such as BioLogic-DTPP-system, Molecular Adsorbent Recycling system (MARS), Prometheus system etc., are discussed. Therapeutic apheresis in organ transplantation is mentioned. TA in organ transplantation offers new horizonts for ABO incompatible organ transplantation. This is discussed for renal-, liver-, heart-, lung-, and hematopoietic progenitor cell transplantation. The application of TA in transplantation is a corner stone of several conditions in ABO incompatible transplantation and enables to develop new strategies, the best organ transplantation in patients even with a high degree of immunonization or performed antibodies thereby expanding the use of living donation. Different clinical application committees have made a gradation of diseases, which are accepted for TA. All these new tendencies have influenced the clinical routine of treatments. The advantages are the elimination of pathologic substances and the interruption of pathogenic reactions. The disadvantages are the unselective elimination of all proteins by the unselective methods, the possible complications and the high costs. The authors try to define with regard to the literature the indications of different methods of TA. Especially in the present time, in which the resources in the health systems decrease enormously, a strong definition of indications for TA is necessary to save the health of our patients and to reduce the costs in future. This fourth edition should be a teaching and working book for all physicians, nurses, scientists, and industries, who are interested in this field. The experiments of modern biotechnologies to try a better imitating of the organ functions will be more and more encouraging, and we understand the pathophysiology of different diseases better and this enable us a more effective therapy in patients with a bad prognosis. Very important are various adsorption methods for plasma or blood of various diseases. This edition will give answers to different questions in this area.
In response to persistent donor organ shortages, organs from marginal donors, such as expanded criteria donors (ECD) and donation after cardiac death (DCD) donors, are now accepted and have been successfully transplanted, reducing the waiting times for transplantation. Especially in Japan, transplantation of DCD kidneys has a relatively long history because of the difficulty or lack of national consensus in accepting brain death, which has made it possible to accumulate considerable clinical experience. Thus, the current organ shortage has stimulated interest in the use of marginal donors for transplantation. On the other hand, however, it is known that these organs have a high rate of delayed graft function and a more complicated postoperative course. These drawbacks have created the greatest clinical challenge in transplantation to date because of the current shortage and limitations of donors using ECD and DCD.This book, prepared by distinguished authorities in their fields, is intended for clinicians and researchers. It highlights the use of marginal donors as a comparatively novel source of transplantation organs and provides a thorough overview of marginal donors from their historical origins to recent clinical applications, including the state-of-the-art science of organ/donor management, procurement, and preservation. Also provided is valuable information on ABO-incompatible donors which extend the availability of donor sources. Each chapter offers an individual analysis of the optimal requirements for the safe management and preservation of organs, including the heart, lung, liver, kidney, pancreas, and pancreatic islets.
As recent advances in immunosuppression and apheresis techniques have opened new avenues for the management of humoral immunity, interest in ABO-incompatible kidney transplantation has been renewed. Moreover, new screening techniques - such as the single antigen bead assay - allow for the detection and definition of very low levels of alloantibody, which has had a positive impact on the treatment possibilities in highly sensitized adult patients with end-stage renal disease. But despite these advances, a theoretical rationale is still missing for both the decision to transplant a sensitized patient and the classification of the transplant as low, medium or high risk. There is also no uniform approach with regard to pre-transplant desensitization protocols, and it is unclear whether particular post-transplant immunosuppression will be required and what would be the best combination treatment. Last but not least, the frequency and actual clinical impact of alloantibodies developed after transplantation on short- and long-term graft survival need to be ascertained. Aimed especially at the clinician, this publication presents recent insights in the characterization and pathogenetic role of humoral immunity in chronic allograft injury and investigates the perspectives for novel immunosuppressive therapies to control antibody production after transplantation.